Protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and
SARS-related emergent zoonotic coronaviruses is urgently needed. We made homotypic …

To combat future severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
and spillovers of SARS-like betacoronaviruses (sarbecoviruses) threatening global health, …

BRCA1 is a breast and ovarian cancer tumor suppressor protein that associates with BARD1
to form a RING/RING heterodimer. The BRCA1/BARD1 RING complex functions as an …

Antibodies to Zika virus (ZIKV) can be protective. To examine the antibody response in
individuals who develop high titers of anti-ZIKV antibodies, we screened cohorts in Brazil and …

Many anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) neutralizing
antibodies target the angiotensin-converting enzyme 2 (ACE2) binding site on viral spike …

Monoclonal antibodies (mAbs) are a focus in vaccine and therapeutic design to counteract
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants. Here, we …

Engineered fusion proteins containing two or more functional polypeptides joined by a
peptide or protein linker are important for many fields of biological research. The separation …

Wide-scale SARS-CoV-2 genome sequencing is critical to tracking viral evolution during the
ongoing pandemic. We develop the software tool, Variant Database (VDB), for quickly …

Broadly neutralizing monoclonal antibodies protect against infection with HIV-1 in animal
models, suggesting that a vaccine that elicits these antibodies would be protective in humans. …

Increased immune evasion by SARS-CoV-2 variants of concern highlights the need for new
therapeutic neutralizing antibodies. Immunization with nanoparticles co-displaying spike …